UK Vaccine Taskforce Leader Under Scrutiny After Investor Meeting
Bingham: My Focus Is On Portfolio, Not Politics
The UK has built one of the biggest and best ‘portfolios’ of COVID-19 vaccine candidates – but there are questions about its transparency and accountability.
You may also be interested in...
Russia seeks WHO endorsement of its Sputnik V vaccine, a UK BioIndustry Association taskforce identifies potential new antibody cocktails, and the European Centre for Disease Prevention and Control considers the best strategies for targeted vaccination programs.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.